The Motley Fool Investing Philosophy: We generally recommend investors buy shares of at least 25 stocks and hold them for at least 5 years. Learn More
| 1 Year | 5 Year | 5 Year Annualized | Since IPO | |
|---|---|---|---|---|
| KRYS | +6.4% | +287.17% | +31.09% | +1,693% |
| S&P | +14.5% | +93.32% | +14.09% | +167% |
Krystal Biotech, Inc. is a biotechnology company focused on developing and commercializing genetic medicines for patients with rare diseases. The company’s wide-ranging pipeline is based on its proprietary redosable HSV vector. The firm is led by an experienced management team, is fully-integrated and has core capabilities in viral vector design, vector optimization, gene therapy manufacturing and commercialization. Krystal was founded by Krish Krishnan & Suma M. Krishnan on April 15, 2016 and is headquartered in Pittsburgh, PA.
Have investors already missed the boat with this stock?
| Q2 2025 | YOY Change | |
|---|---|---|
| Revenue | $96.04M | 36.6% |
| Gross Profit | $87.33M | 40.2% |
| Gross Margin | 90.93% | 2.3% |
| Market Cap | $3.97B | -24.3% |
| Market Cap / Employee | $14.45M | 0.0% |
| Employees | 275 | 20.1% |
| Net Income | $38.33M | 146.2% |
| EBITDA | $40.85M | 77.2% |
Currently no data to display
Currently no data to display.
Currently no data to display.
| Q2 2025 | YOY Change | |
|---|---|---|
| Net Cash | $353.83M | 2.3% |
| Accounts Receivable | $111.44M | 7.9% |
| Inventory | 31 | 154.9% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Long Term Debt | $8.06M | 27.5% |
| Short Term Debt | $1.62M | 18.8% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Return On Assets | 14.27% | 1.0% |
| Return On Invested Capital | -7.63% | 3.7% |
| Q2 2025 | YOY Change | |
|---|---|---|
| Free Cash Flow | $50.83M | 1059.1% |
| Operating Free Cash Flow | $52.73M | 1365.1% |
| Metric | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | YoY Change |
|---|---|---|---|---|---|
| Price to Earnings | 102.98 | 52.43 | 43.42 | 27.96 | -44.37% |
| Price to Book | 6.23 | 5.09 | 5.49 | 4.03 | -38.45% |
| Price to Sales | 22.54 | 16.11 | 16.15 | 11.38 | -65.23% |
| Price to Tangible Book Value | 6.23 | 5.09 | 5.49 | 4.03 | -38.45% |
| Price to Free Cash Flow TTM | 93.75 | 39.28 | 41.65 | 22.05 | - |
| Enterprise Value to EBITDA | 133.50 | 95.22 | 126.38 | 83.65 | -60.57% |
| Free Cash Flow Yield | 1.1% | 2.5% | 2.4% | 4.5% | - |
| Return on Equity | 6.4% | 10.3% | 13.9% | 15.6% | 9.94% |
| Total Debt | $7.48M | $7.26M | $9.66M | $9.68M | 25.94% |
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.
